Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Am J Kidney Dis. 2010 Aug 14;56(5):823–831. doi: 10.1053/j.ajkd.2010.05.023

Table 3.

Dosing accuracy in the combined cohort

Clinical variables1 Clinical + eGFR 2 Clinical + eGFR + Genes3
UAB cohort R2 22.6% 25.2% 37.8%
UIC cohort R2 28.0% 29.0% 42.6%
Combined cohort R2 22.8% 25.3% 38.0%

Note: Combined cohort includes University of Alabama at Birmingham and University of Illinois at Chicago participants. eGFR (estimated glomerular filtration rate) is based on National Kidney Foundation staging using the Modification of Diet in Renal Disease Study equation. Patients eGFR >60 in mL/min/1.73 m2 were categorized as having no/mild kidney impairment, those with eGFR =30–59 in mL/min/1.73 m2 as having moderate kidney impairment and those with eGFR <30 in mL/min/1.73 m2 ml/min/1.73 m2 as having severe kidney impairment. Patients receiving maintenance dialysis were categorized as having severe kidney impairment.

1

Clinical variables include age, gender, race, weight and concurrent amiodarone use

2

Clinical + eGFR includes clinical variables and eGFR category.

3

Clinical + eGFR + genes includes clinical variables, eGFR category and CYP2C9 and VKORC1 genotype (CYP2C9 variant genotype includes *2, *3 alleles among European Americans and *2, *3, *5, *6 and *11 alleles among African Americans; VKORC1 variant refers to −1173C>T allele, and includes genotypes TT or CT).